Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

EP262

Phase 2Small molecule

EEscient Pharmaceuticals, Inc

EP262 is one of 102 small molecule programs targeting Urticaria. It is currently in Phase 2.

3

Indications

4

Total Trials

0

Active Trials

101

Competitors

Pipeline

Status by Indication[3][1]

Indication

UrticariaActive, not recruiting

Atopic DermatitisActive, not recruiting

Chronic Spontaneous UrticariaActive, not recruiting

UrticariaPhase 1

Active, not recruiting

Atopic DermatitisPhase 2

Active, not recruiting

Chronic Spontaneous UrticariaPhase 2

Active, not recruiting

Competition

Competitive Landscape

508 competitors in Atopic Dermatitis

#DrugCompanyPhaseTrials

Olumiant

Rezzayo

Daliresp

Skyrizi

Cytosar

Fludara

Celestone

SSchering-Plough

Immunotherapy

Bristol-Myers Squibb

Broncho-Vaxom

EBGLYSS

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Absorption1 trial

An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP262 Following Single-Dose Oral Administration

Completed·EEscient Pharmaceuticals, Inc·Phase 1·NCT06645704·10 enrolled

Chronic Spontaneous Urticaria1 trial

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

Terminated·EEscient Pharmaceuticals, Inc·Phase 2·NCT06077773·113 enrolled

Atopic Dermatitis1 trial

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

Completed·EEscient Pharmaceuticals, Inc·Phase 2·NCT06144424·32 enrolled

Urticaria1 trial

Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

Completed·EEscient Pharmaceuticals, Inc·Phase 1·NCT06050928·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for EP262. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EP262 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EP262. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Escient Pharmaceuticals, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEscient Pharmaceuticals, Inc

Related News